Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update
Belite Bio announced FDA acceptance of its New Drug Application (NDA) for tinlarebant with Priority Review, targeting approval for treatment of Stargardt disease type 1 (STGD1) by February 12, 2027. Positive secondary endpoint data from the Phase 3 DRAGON trial showed a significant reduction in toxic bisretinoid accumulation, supporting clinical ef…